Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 18, 2025
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 07, 2023
Towards more Diversity in Neuro-oncology Leadership-the DivINe Initiative.
Journal: Neuro-oncology
Published: September 22, 2023
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 26, 2023
Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
Journal: Journal of neuro-oncology
Published: June 01, 2022
Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
Journal: The Lancet. Oncology
Published: July 09, 2021
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Journal: Neuro-oncology advances
Published: November 25, 2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Journal: Annals of clinical and translational neurology
Published: November 13, 2019
Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States.
Journal: Neuro-oncology practice
Published: August 07, 2019
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
Journal: Journal of neuro-oncology
Published: June 20, 2019
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Journal: Journal of neuro-oncology
Published: May 01, 2019
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Journal: Neuro-oncology
Published: June 14, 2018
Last Updated: 09/26/2026